Recent Comments

Comment RSS

Emphysema News and Research RSS Feed - Emphysema News and Research

Emphysema is a debilitating disease that afflicts more than three million Americans. The disease is caused primarily by smoking and leads to a progressive, irreversible breakdown of lung tissue. This breakdown reduces the amount of lung tissue available for gas exchange and also impairs the lung's ability to inflate and deflate normally. As the disease advances, the most damaged areas of the lung over inflate within the chest cavity, trapping air and preventing the healthier lung areas from functioning normally. Eventually breathing becomes more difficult, leaving patients constantly feeling out-of-breath.

Scientists explore various imaging techniques to gain new insight into lung disease

21. November 2009 00:26
Chronic obstructive pulmonary disease (COPD), a respiratory disease commonly known as chronic bronchitis or emphysema, is the fourth leading cause of death worldwide. 600 million people live with COPD and while researchers have yet to find any real treatment or cure, Grace Parraga of Robarts Research Institute at The University of Western Ontario in London, Canada, is using various imaging techniques to gain new insight into the disease. [More]

Posted in: Medical Condition News

Tags: , , , , ,

New research studies seek to improve diagnosis and treatment for emphysema and other lung diseases

20. November 2009 01:01
The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Both studies are now accepting new participants. [More]

Posted in: Medical Condition News | Healthcare News

Tags: , , , , ,

Smoking cigarettes leads to back pain and spine problems, show recent studies

19. November 2009 02:59
Smoking cigarettes not only contributes to lung cancer and emphysema, it also leads to back pain and spine problems, according to recent studies and observations from leading neurosurgeons in Chicago. [More]

Canadian comedian helps raise awareness about COPD

18. November 2009 07:32
COPD is no joke to Canadian comedian Mary Walsh. "It's shocking that so few Canadians know about COPD considering it's the fourth leading cause of death in this country," says Mary Walsh, spokesperson for The Canadian Lung Association. [More]

Posted in: Medical Condition News

Tags: , , , , ,

Most patients with HAE have prodromal symptoms that signal an oncoming HAE attack

9. November 2009 01:52
Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. [More]

C1-INH concentrate, an effective therapy to treat acute swelling attacks at any body location for HAE

9. November 2009 00:11
Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. [More]

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

7. November 2009 02:00
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. [More]

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

7. November 2009 01:16
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. [More]

CHANTIX/CHAMPIX raises hope for quitting smoking

5. November 2009 01:50
New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP). [More]

SBRT stops the growth of cancer for 98% of patients with NSCLC

3. November 2009 07:19
Stereotactic body radiation therapy (SBRT) stopped the growth of cancer at its original site in the lung for three years among nearly 98 percent of patients with early non-small cell lung cancer (NSCLC) who are unable to have the cancer surgically removed, according to an updated three-year study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). [More]

Medico's Hirata to distribute Broncus Technologies' LungPoint system and Yield catheters in Japan

3. November 2009 04:51
Broncus Technologies, Inc., a medical device company focused on developing and commercializing innovative solutions for lung diseases, announced today at the American College of Chest Physicians CHEST 2009 meeting that it has entered into an exclusive agreement with Medico's Hirata as the sole distributor of their LungPoint system and Yield catheters in Japan. [More]

Posted in: Device / Technology News

Tags: , , , , , ,

Interim data from Schering-Plough's narlaprevir Phase IIa study

3. November 2009 03:02
Schering-Plough Corporation today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. [More]

NHLBI survey results reveal COPD awareness continues to grow in the United States

3. November 2009 01:05
Awareness of COPD-chronic obstructive pulmonary disease-continues to grow in the United States, according to national survey results released today by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. [More]

Posted in: Medical Condition News

Tags: , , , , , , , ,

John C. Lincoln Hospital first to use commercially-available LungPoint system

2. November 2009 10:39
Broncus Technologies, Inc., a medical device company focused on developing minimally-invasive innovations for lung diseases, announced today at the American College of Chest Physicians CHEST 2009 meeting that John C. Lincoln Hospital in Phoenix is the first hospital in the U.S. to use the commercially-available LungPoint system. [More]

Posted in: Device / Technology News | Healthcare News

Tags: , , , , ,

Schering-Plough receives FDA complete response letter regarding PEGINTRON

31. October 2009 03:09
Schering-Plough Corp. announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.